Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics By Rznomics Inc. May 15, 2025 Updated May 15, 2025 Rznomics Logo (PRNewsfoto/Rznomics Inc.) By Rznomics Inc.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss. The centerpiece of the agreement is ...

Eli Lilly and Co. and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned investment of up to $250 million in the collaboration over ...

An existing partnership was set to expire in 2027, but this program, named the Lilly-Purdue 360 initiative, will expand the collaboration and keep it running until at least 2032.